Last updated: September 25, 2026
Equate omeprazole is a private-label OTC product positioned around low-cost, delayed-release delivery of omeprazole 20 mg. Its commercial value depends less on the active ingredient, which is widely genericized, and more on enteric protection, manufacturing yield, stability, packaging, retail execution, and differentiated dosage forms. The strongest opportunities are lower-cost multiparticulate systems, sugar-free and vegetarian presentations, smaller pack sizes, and formulations that improve adherence without creating new regulatory or patent exposure.
What is Equate omeprazole?
Equate omeprazole is Walmart’s private-label version of OTC omeprazole delayed-release medicine used for frequent heartburn. The common U.S. presentation contains omeprazole equivalent to 20 mg and is marketed for a 14-day course, consistent with the OTC proton-pump inhibitor labeling framework.
Equate is a brand platform rather than one globally uniform formulation. The manufacturer, inactive ingredients, capsule shell, dosage form, package configuration, and supply source can vary by product code and procurement period. Public product labels commonly identify a delayed-release capsule or tablet with an enteric-coated omeprazole core, along with excipients such as:
| Formulation function |
Common excipient classes |
| Pellet or granule substrate |
Sugar spheres, microcrystalline cellulose, starch-based carriers |
| Drug-layer binder |
Hypromellose, povidone, hydroxypropyl cellulose |
| Enteric polymer |
Methacrylic acid copolymers, cellulose acetate phthalate, or related acid-resistant polymers |
| Plasticizer |
Triethyl citrate, polyethylene glycol, or similar materials |
| Anti-tacking agent |
Talc, colloidal silicon dioxide |
| Opacifier or colorant |
Titanium dioxide, iron oxides, approved capsule colorants |
| Capsule shell |
Gelatin or hypromellose |
| Capsule-processing aids |
Sodium lauryl sulfate, polysorbate, magnesium stearate, depending on the product |
The exact composition must be confirmed from the applicable Drug Facts label, Structured Product Labeling record, and manufacturing authorization for the specific Equate SKU.
Why does omeprazole require a specialized excipient system?
Omeprazole is acid-labile. Exposure to gastric acid can degrade the active ingredient before absorption. The excipient strategy therefore has two linked objectives:
- Protect omeprazole during manufacture and storage.
- Prevent release in the stomach while allowing dissolution in the higher-pH environment of the small intestine.
A conventional immediate-release capsule is unsuitable for reliable oral delivery. Commercial omeprazole products normally use enteric-coated pellets, granules, tablets, or capsules containing coated units.
What is the typical omeprazole multiparticulate design?
A common architecture is:
- Inert starter pellet or matrix particle.
- Drug-layer application containing omeprazole and binder.
- Protective seal coat.
- Enteric coating.
- Filling into a hard capsule or compression into a delayed-release tablet.
The seal coat separates the active layer from acidic or reactive components in the enteric system. The enteric layer remains intact in gastric fluid and dissolves after the dosage form reaches a higher-pH intestinal environment.
This architecture permits several commercial controls:
- Particle-size adjustment for release consistency.
- Independent coating of each pellet.
- Better distribution of the active ingredient across the dosage unit.
- Capsule filling at high speed.
- Potential sprinkle or sachet formats.
- Lower dependence on a single compressed tablet matrix.
The main technical risks are coating defects, premature drug release, omeprazole degradation, pellet agglomeration, variable dissolution, and sensitivity to moisture.
What excipients are most important in Equate omeprazole?
Enteric polymers
The enteric polymer is the principal functional excipient. Methacrylic acid copolymers are widely used because they can be selected for dissolution at a target pH. Polymer grade, coating weight, plasticizer level, and curing conditions directly affect acid resistance and intestinal release.
A thinner coating lowers cost and may improve release after gastric transit, but it increases the risk of acid-stage failure. An overly thick coating can delay or reduce release and raise manufacturing cost.
Seal-coat materials
A seal coat protects the omeprazole layer from the enteric polymer and from moisture. Hypromellose, povidone, and related film-forming materials can be used. The seal coat must be continuous but thin enough to preserve dissolution performance.
Alkalizing or stabilizing agents
Omeprazole stability can improve in a mildly alkaline microenvironment. Formulators may use alkaline excipients or buffering components to limit acid-mediated degradation. The choice must be balanced against taste, hygroscopicity, dissolution behavior, and compatibility with the coating system.
Plasticizers and anti-tacking agents
Plasticizers reduce brittleness in the enteric film. Triethyl citrate and polyethylene glycol are common examples. Talc and colloidal silicon dioxide can reduce sticking during fluid-bed coating, although excessive levels can interfere with film formation or dissolution.
Capsule-shell materials
Gelatin capsules remain cost-efficient and widely available. Hypromellose capsules provide a vegetarian alternative and may support positioning around dietary preferences. They can have different moisture-transfer characteristics, which affects the stability program and packaging specification.
How does Equate’s excipient strategy affect manufacturing cost?
The largest cost drivers are coating time, active-layer uniformity, yield loss, stability controls, and packaging requirements.
| Cost driver |
Commercial effect |
| Multiple coating stages |
Raises equipment time and labor but improves protection and release control |
| Enteric polymer loading |
Influences raw-material cost and dissolution performance |
| Pellet yield |
Defects and agglomeration increase batch losses |
| Moisture sensitivity |
May require high-barrier bottles, desiccants, or blister packaging |
| Capsule filling |
Supports high throughput but creates fill-weight and segregation controls |
| Analytical testing |
Requires acid-stage, buffer-stage, assay, impurities, and stability testing |
| Supplier qualification |
Limits substitution of polymers, capsule shells, and coating aids |
A low-cost Equate product is unlikely to be optimized through the lowest possible excipient bill alone. The economic target is total delivered cost. A more expensive polymer can reduce coating defects, shorten process time, lower rejects, or improve shelf life.
Fluid-bed coating is typically the critical process step. A formulation with fewer coating layers may appear cheaper but can create higher variance in acid resistance and release. The commercial optimum is usually the formulation that meets dissolution and stability requirements with the lowest failure rate.
What commercial opportunities exist for Equate omeprazole?
Can sugar-free and vegetarian omeprazole gain share?
Yes. A sugar-free formulation could appeal to consumers avoiding sucrose-based pellet substrates or seeking a simpler inactive-ingredient profile. A hypromellose capsule could support vegetarian positioning.
The opportunity is commercially relevant but limited by the need to preserve:
- Acid resistance.
- Omeprazole stability.
- Capsule-machine performance.
- Comparable dissolution.
- Low moisture uptake.
- Consumer acceptance of any altered capsule appearance.
A sugar-free presentation may require replacing sugar spheres with microcrystalline cellulose or another inert substrate. That change can alter pellet density, drug-layer adhesion, coating uniformity, and capsule fill volume.
Can Equate expand into 10 mg or shorter-course products?
A 10 mg presentation could target consumers seeking lower-dose self-care or step-down use. It would require appropriate labeling, dosing instructions, and regulatory support. A smaller dose also creates content-uniformity challenges because the active mass is lower relative to the excipient load.
A shorter-course pack, such as seven capsules, could reduce consumer cost and minimize unused medication. Larger 14-dose and 42-dose configurations support household use and repeat purchase but can carry more inventory and increase the chance of prolonged self-treatment outside label directions.
Are sprinkle or sachet formulations attractive?
Multiparticulate omeprazole is compatible with sprinkle delivery, provided the pellets remain intact and are not crushed or chewed. Potential formats include:
- Capsules that can be opened and sprinkled.
- Unit-dose sachets.
- Oral granules.
- Pediatric or swallowing-challenged presentations.
These formats create differentiation in a mature generic category. They also create higher packaging, taste-masking, moisture-control, and usability requirements. A sprinkle product must communicate that the coated pellets should not be chewed.
Can combination products create additional value?
Potential combinations include omeprazole with antacids, alginates, or other heartburn-relief ingredients. Combination products may improve consumer convenience but introduce regulatory complexity, separate compatibility questions, and additional labeling requirements.
A combination can also reduce the simplicity advantage of private-label omeprazole. For a retailer, the strongest business case is a format that improves perceived value without materially increasing manufacturing, testing, or inventory complexity.
What is the FDA regulatory status of Equate omeprazole?
OTC omeprazole products are regulated under the FDA framework for OTC proton-pump inhibitors and applicable approved labeling. The core regulatory requirements include:
- Compliance with the applicable OTC monograph or approved application pathway.
- Appropriate Drug Facts labeling.
- Manufacturing under current good manufacturing practice.
- Demonstration of identity, strength, quality, purity, and stability.
- Delayed-release performance consistent with the product’s regulatory basis.
- Appropriate testing for degradation products and dissolution.
OTC omeprazole is marketed for frequent heartburn treatment, generally with a 14-day course and defined administration instructions. It is not labeled as immediate relief for occasional heartburn. Product claims must remain consistent with the authorized labeling.
What is the Orange Book status of omeprazole?
The Orange Book lists approved omeprazole drug products and related delayed-release dosage forms. It is relevant for prescription omeprazole products and approved applications, but a private-label OTC product may not map cleanly to one branded Orange Book entry. The regulatory status depends on the specific application, manufacturer, dosage form, and marketing pathway.
A product-level review should distinguish:
- OTC omeprazole under the applicable monograph or OTC authorization.
- Prescription omeprazole capsules and tablets.
- Omeprazole and sodium bicarbonate products.
- Combination products.
- Authorized generic arrangements.
- Private-label products manufactured under contract.
What patents protect omeprazole and its formulations?
The core omeprazole compound is no longer a meaningful blocking patent position in the U.S. The principal commercial barriers now arise from formulation execution, manufacturing know-how, trademarks, regulatory compliance, and supply-chain scale.
Potentially relevant patent categories include:
| Patent category |
Relevance to Equate |
| Omeprazole compound patents |
Generally expired or commercially exhausted in the U.S. |
| Enteric-coated pellet patents |
May cover specific layering, polymer, or release designs |
| Stabilized omeprazole compositions |
May cover alkaline systems, buffers, or impurity control |
| Delayed-release tablets |
May cover compression, coating, or matrix architecture |
| Combination products |
May cover omeprazole with bicarbonate or other active ingredients |
| Manufacturing patents |
May cover coating processes, pellet formation, or scale-up |
| Method-of-use patents |
More relevant to branded indications than standard OTC heartburn use |
| Trade secrets |
Often more important than patents for coating parameters and process controls |
Patent clearance must be conducted against the exact formulation and process. A generic formulation can avoid a patent claim by changing the polymer, excipient ratio, coating sequence, particle architecture, or manufacturing conditions. That can create a tradeoff between freedom to operate and process robustness.
When does omeprazole lose exclusivity, and what is the generic launch risk?
The active ingredient has already lost U.S. market exclusivity. Generic and private-label competition is established. The commercial risk is therefore not a future patent cliff for the molecule. It is ongoing price erosion and retailer substitution.
| Risk factor |
Likely impact |
| Multiple omeprazole suppliers |
High pressure on wholesale and retail pricing |
| Retailer private-label purchasing |
High buyer power and annual repricing |
| Formulation similarity |
Low consumer switching costs |
| Supply interruption |
Potential short-term pricing opportunity |
| OTC shelf placement |
Strong effect on velocity and market share |
| Branded advertising |
Limited advantage for basic 20 mg products |
| Differentiated delivery format |
Potential margin protection |
Paragraph IV litigation is more relevant to active prescription products and later entrants challenging listed patents. Standard OTC private-label omeprazole is generally exposed to formulation and regulatory competition rather than a classic branded-innovator Paragraph IV launch event.
Which companies compete with Equate omeprazole?
The competitive field includes:
- Store brands sold by major retailers.
- Prilosec OTC and other branded omeprazole products.
- Generic omeprazole manufacturers.
- Amazon private-label and e-commerce sellers.
- Alternative proton-pump inhibitors such as lansoprazole and esomeprazole.
- H2-receptor antagonists such as famotidine.
- Antacid and alginate products for faster symptom relief.
Equate’s advantage is distribution and price visibility. Its disadvantages are limited brand differentiation and dependence on external manufacturers or supply partners. The most important competitive variables are retail price, count size, in-stock performance, package clarity, capsule size, consumer trust, and perceived speed of relief.
What licensing and manufacturing opportunities exist?
The most attractive licensing opportunities are in platform technologies rather than the omeprazole molecule:
Excipient and coating platforms
Licensors can offer:
- Low-temperature enteric coating.
- Faster-curing polymers.
- Moisture-resistant seal coats.
- Sugar-free pellet substrates.
- High-solids coating systems.
- Improved coating uniformity.
- Reduced solvent use.
- Continuous or semi-continuous pellet processing.
Contract manufacturing
A contract manufacturer can differentiate through:
- Validated multiparticulate coating capacity.
- High-throughput capsule filling.
- Private-label regulatory support.
- U.S. OTC packaging and serialization capability.
- Stability data packages.
- Multi-site supply continuity.
- Flexible pack-size production.
Manufacturing IP barriers are usually process-specific. The most defensible know-how may be the combination of coating parameters, inlet and outlet temperature controls, spray rate, atomization, curing, packaging, and impurity management rather than a single excipient.
How strong is the patent estate for Equate omeprazole?
The patent estate is weak at the molecule level and potentially moderate at the formulation and process level. Commercial defensibility is strongest where the product has:
- A differentiated dosage form.
- A proprietary coating process.
- A formulation with measurable stability or dissolution advantages.
- A protected combination product.
- A strong retailer-exclusive arrangement.
- Reliable low-cost manufacturing.
- Regulatory data that competitors cannot easily replicate.
For ordinary 20 mg delayed-release capsules, the key moat is operational rather than patent-based. A competitor with an equivalent regulatory product can usually enter through price, supply, or distribution.
What is the revenue exposure for an Equate omeprazole supplier?
Revenue exposure is concentrated in unit volume and contract retention. Private-label suppliers usually face:
- Annual price negotiations.
- Dual sourcing requirements.
- Retailer inventory controls.
- Forecast volatility.
- Shorter product refresh cycles.
- Margin compression as additional suppliers qualify.
A supplier with one standard capsule presentation has high substitution risk. A supplier with multiple formats, validated coating platforms, and a differentiated manufacturing process has greater account durability.
The highest-value commercial strategy is to combine a low-cost base product with one or more margin-supporting variants:
- Standard 20 mg delayed-release capsule.
- Sugar-free or vegetarian capsule.
- Smaller count package.
- Sprinkle or unit-dose format.
- Larger household pack.
- Related combination or adjunctive heartburn product.
Key Takeaways
- Equate omeprazole is a private-label OTC product whose value depends on reliable delayed-release performance and low delivered cost.
- The critical excipient system includes a drug-layer binder, protective seal coat, enteric polymer, plasticizer, anti-tacking agent, and moisture-controlled package.
- Multiparticulate pellet technology provides the strongest balance of acid protection, manufacturing flexibility, and potential dosage-form differentiation.
- Omeprazole’s core U.S. compound exclusivity is no longer a meaningful barrier. Formulation patents, process patents, trade secrets, and regulatory execution are more relevant.
- The strongest commercial opportunities are sugar-free, vegetarian, sprinkle, sachet, lower-dose, and flexible-count presentations.
- Standard 20 mg capsules face intense price competition. Differentiated delivery systems can improve margin and retailer retention.
- Manufacturing scale, coating yield, stability, packaging, and supply continuity are more important than molecule-level patent protection.
FAQs About Equate Omeprazole Excipients and Commercial Strategy
Does Equate omeprazole contain gelatin?
Some Equate omeprazole capsule products may use gelatin capsules, while other products may use hypromellose shells. The answer depends on the specific SKU and current package label.
Is Equate omeprazole sugar-free?
The answer depends on the pellet substrate and product formulation. Omeprazole capsules using sugar spheres may not support a sugar-free positioning. A product using microcrystalline cellulose or another non-sucrose carrier could.
Can omeprazole pellets be used in a pediatric sprinkle product?
Yes, multiparticulate delayed-release pellets can support sprinkle delivery. The product must preserve pellet integrity, control taste, meet dissolution specifications, and carry directions not to crush or chew the pellets.
Which excipient most affects omeprazole dissolution?
The enteric polymer system has the largest direct effect on gastric acid resistance and intestinal release. Coating thickness, polymer grade, plasticizer ratio, and curing conditions are equally important in the final performance.
Is a new patent required to launch a private-label omeprazole product?
A new patent is not generally required to launch a compliant private-label product. The sponsor must establish regulatory compliance and freedom to operate for the selected formulation, process, packaging, and claims.
References
-
U.S. Food and Drug Administration. (2022). Over-the-counter monograph M006: Proton pump inhibitor products for oral administration. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Drug Facts labeling for over-the-counter human drug products. FDA.
-
U.S. National Library of Medicine. (2024). DailyMed: Omeprazole delayed-release capsule product labeling. National Library of Medicine.
-
U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
-
World Health Organization. (2006). The International Pharmacopoeia: Omeprazole. World Health Organization.
